The litigation centers on claims that Capricor Therapeutics failed to disclose critical modifications to the statistical analysis plan used for its Phase 3 HOPE-3 clinical trial. According to the complaint, the company submitted a Biologics License Application to the FDA without securing agreement on these changes, masking significant risks to the product's regulatory approval. These undisclosed adjustments reportedly undermined the evidence of effectiveness required by federal regulators.

Financial fallout from these disclosures was severe. Following FDA updates on July 27, 2026, Capricor’s stock price plummeted 64%, dropping $12.70 per share. The downward pressure intensified after an FDA advisory committee voted 9-3 against the efficacy of Deramiocel for treating DMD-associated cardiomyopathy. By July 30, the stock saw an additional 36% decline, closing at $4.19. Robbins LLP, the firm representing the class, is now coordinating legal efforts for shareholders seeking to recover losses. Participation in the litigation carries no upfront costs for investors, as the firm operates on a contingency fee basis.